Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA) (NFKBIA)

Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA), commonly known as IkappaBalpha, is a critical regulatory protein that serves as the primary inhibitor of the NF-kappaB signaling pathway [1, 6]. In its inactive state, NFKBIA binds to NF-kappaB transcription factor dimers in the cytoplasm, masking their nuclear localization signals and preventing their translocation to the nucleus [3, 11]. Upon stimulation by pro-inflammatory cytokines, growth factors, or pathogens, NFKBIA is phosphorylated by the IkappaB kinase (IKK) complex, leading to its ubiquitination and subsequent degradation by the 26S proteasome [7, 14]. This degradation releases NF-kappaB, allowing it to enter the nucleus and activate the transcription of genes involved in inflammation, immune response, and cell survival [4, 12]. Dysregulation of NFKBIA, including loss-of-function mutations or constitutive degradation, is associated with various cancers, chronic inflammatory diseases, and immunodeficiencies [2, 15]. In oncology, NFKBIA is a major therapeutic target; drugs such as proteasome inhibitors (e.g., bortezomib) work by preventing its degradation, thereby maintaining NF-kappaB in an inactive state to treat malignancies like multiple myeloma [16, 17]. Furthermore, glucocorticoids exert their anti-inflammatory effects partly by upregulating NFKBIA expression, highlighting its central role in modulating immune signaling [14, 19].

Other names

IkappaBalphaIKBAMAD-3NFKBINF-kappa-B inhibitor alphaEDAID2Major histocompatibility complex enhancer-binding protein MAD3

Drugs targeting this pathway primarily act by preventing the degradation of the NFKBIA protein (IkappaBalpha) or by inducing its expression. Proteasome inhibitors like bortezomib block the 26S proteasome, preventing the breakdown of phosphorylated IkappaBalpha and thus keeping NF-kappaB sequestered and inactive in the cytoplasm [14, 16]. Glucocorticoids like dexamethasone increase the transcription of the NFKBIA gene, leading to elevated levels of the inhibitor protein [14]. Other agents, such as IKK inhibitors, prevent the phosphorylation of IkappaBalpha, which is the prerequisite signal for its ubiquitination and degradation [16].